Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

August 31, 2004

Conditions
Ovarian CancerFallopian Tube NeoplasmsPeritoneal Neoplasms
Interventions
BIOLOGICAL

ACA 125

Trial Locations (11)

10117

Clinic for Gynecology and Gyn. Oncology, Humboldt University, Berlin

17487

Gynecologic Clinic of the Ernst-Moritz-Arndt-University, Greifswald

24105

University Clinic Schleswig-Holstein, Campus Kiel, Clinic for gynecology and obstetrics, Kiel

35033

Clinic of the Philipps University Marburg, Clinic for gynecology, gyn. endocrinology and oncology, Marburg

39108

Otto-von-Guericke University, University Gynecological Hospital, Magdeburg

40217

Gynecologic Hospital, Düsseldorf

45122

University Gynecologic Hospital, Essen

60596

University Gynecologic Hospital, Frankfurt

65199

Clinic for Gnyecology and gyn. Oncology HSK, Wiesbaden

89075

University Gynecological Hospital, Ulm

01307

University Clinic Carl Gustav Carus, Gynecological hospital, Dresden

All Listed Sponsors
lead

AGO Study Group

OTHER

NCT00103545 - Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | Biotech Hunter | Biotech Hunter